Association of antipsychotic use with raised eosinophil count

Tsamakis,Konstantinos; Mueller,Christoph; Hortis,Ioannis; Kallergi,Maria; Tolos,Ioannis; Alevyzakis,Evangelos; Siafakas,Nikolaos; Ouranidis,Andreas; Tsiptsios,Dimitrios; Kympouropoulos,Stylianos; Spandidos,Demetrios A.; Smyrnis,Nikolaos; Rizos,Emmanouil

doi:10.3892/etm.2021.9944

Association of antipsychotic use with raised eosinophil count

Authors:
- Konstantinos Tsamakis
- Christoph Mueller
- Ioannis Hortis
- Maria Kallergi
- Ioannis Tolos
- Evangelos Alevyzakis
- Nikolaos Siafakas
- Andreas Ouranidis
- Dimitrios Tsiptsios
- Stylianos Kympouropoulos
- Demetrios A. Spandidos
- Nikolaos Smyrnis
- Emmanouil Rizos
View Affiliations

Affiliations: Second Department of Psychiatry, University General Hospital ‘Attikon’, National and Kapodistrian University of Athens, Athens 12462, Greece, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AF, UK, Department of Biomedical Engineering, University of West Attica, Campus I, Athens 12243, Greece, Second Laboratory of Microbiology, University General Hospital ‘ATTIKON’, National and Kapodistrian University of Athens, Medical School, Athens 12462, Greece, Department of Pharmaceutical Technology, School of Pharmacy, Aristotle University of Thessaloniki, Thessaloniki 54636, Greece, Department of Neurophysiology, South Tyneside and Sunderland NHS Foundation Trust, Sunderland SR47TP, UK, Laboratory of Clinical Virology, School of Medicine, University of Crete, Heraklion 71003, Greece
Published online on: March 19, 2021 https://doi.org/10.3892/etm.2021.9944
Article Number: 513
Copyright: © Tsamakis et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The current study aimed to assess the possibility of an association between first and second generation antipsychotic medication and raised eosinophil count. A total of 22 in‑patients at the psychiatric unit of the University General Hospital ‘Attikon’, a tertiary hospital, were included in the present study. Patients had received antipsychotic monotherapy and did not have any co‑morbidities or require additional treatments. Patients were monitored weekly and their eosinophil count was assessed. One‑way ANOVA and summary measures analysis were applied to study the effect of time and medication type on the absolute eosinophil concentration (or relative percentage) for each patient. The differences in mean eosinophil concentrations or relative percentage by patient and time were also assessed. An increase in the absolute concentration and the relative percentage of eosinophils over time was observed in patients receiving Olanzapine, Haloperidol and Aripiprazole. However, there was no difference between individual medications. In conclusion, antipsychotics may be associated with increased eosinophil count over time; however, larger studies involving more patients and a longer follow‑up are required to reach a definitive conclusion.

View Figures

View References

1	Klion AD: Eosinophilia: A pragmatic approach to diagnosis and treatment. Hematology Am Soc Hematol Educ Program, 92-97: 2015.
2	Rauscher C and Freeman A: Drug-induced eosinophilia. Allergy Asthma Proc. 39:252–256. 2018.PubMed/NCBI View Article : Google Scholar
3	Kadiyala PK, Ahmed MA, Pinto DA and Mathai JP: Clozapine induced eosinophilia: An often neglected important adverse effect. Indian J Psychiatry. 57:429–430. 2015.PubMed/NCBI View Article : Google Scholar
4	Gentile S: Safety concerns associated with second-generation antipsychotic long-acting injection treatment. A systematic update. Horm Mol Biol Clin Investig 36, 2018.
5	Rettenbacher MA, Hofer A, Kemmler G and Fleischhacker WW: Neutropenia induced by second generation antipsychotics: A prospective investigation. Pharmacopsychiatry. 43:41–44. 2010.PubMed/NCBI View Article : Google Scholar
6	Huang J, Yu Y, Lin W, Zhang D, Deng Z and Ding Q: Olanzapine-induced peripheral eosinophilia and eosinophilic pleural effusion: A case report. Medicine (Baltimore). 97(e9996)2018.PubMed/NCBI View Article : Google Scholar
7	Tournikioti K, Douzenis A, Antoniadou A, Papazahos K, Moschos C, Papageorgiou C and Rizos EN: Eosinophilia Associated With Olanzapine. J Clin Psychopharmacol. 36:180–181. 2016.PubMed/NCBI View Article : Google Scholar
8	Mathias S, Schaaf LWN and Sonntag A: Eosinophilia associated with olanzapine. J Clin Psychiatry. 63:246–247. 2002.PubMed/NCBI View Article : Google Scholar
9	Penchilaiya V, Kuppili PP, Preeti K and Bharadwaj B: DRESS syndrome: Addressing the drug hypersensitivity syndrome on combination of Sodium Valproate and Olanzapine. Asian J Psychiatr. 28:175–176. 2017.PubMed/NCBI View Article : Google Scholar
10	Vang T, Rosenzweig M, Bruhn CH, Polcwiartek C, Kanters JK and Nielsen J: Eosinophilic myocarditis during treatment with olanzapine-report of two possible cases. BMC Psychiatry. 16(70)2016.PubMed/NCBI View Article : Google Scholar
11	Raz A, Eilam O, Hayek T, Bergman R and Yungerman T: A Case report of olanzapine-induced hypersensitivity syndrome. Am J Med Sci. 321:156–158. 2001.PubMed/NCBI View Article : Google Scholar
12	Taleb S, Zgueb Y, Ouali U, Jomli R, Kort Y and Nacef F: Drug reaction with eosinophilia and systemic symptoms syndrome related to aripiprazole therapy. J Clin Psychopharmacol. 39:691–693. 2019.PubMed/NCBI View Article : Google Scholar
13	Christoffersen RK, Vestergård LD, Høimark L and Vesterby A: Eosinophilic myocarditis and sudden unexpected death in a younger patient treated with antipsychotics. Ugeskr Laeger. 173:2799–2800. 2011.PubMed/NCBI(In Danish).
14	Hagiwara H, Fukushima A, Iwano H and Anzai T: Refractory cardiac myocarditis associated with drug rash with eosinophilia and systemic symptoms syndrome due to anti-bipolar disorder drugs: A case report. Eur Hear J Case Rep. 2(yty100)2018.PubMed/NCBI View Article : Google Scholar
15	Chen L, Tan P and Tan X: Case report of eosinophilia induced by quetiapine. Shanghai Arch psychiatry. 27:374–377. 2015.PubMed/NCBI View Article : Google Scholar
16	Rizos E, Tsigkaropoulou E, Lambrou P, Kanakaki M, Chaniotou A, Alevyzakis E and Liappas I: Risperidone-induced acute eosinophilic pneumonia. In Vivo. 27:651–653. 2013.PubMed/NCBI
17	Lee J, Takeuchi H, Fervaha G, Powell V, Bhaloo A, Bies R and Remington G: The effect of clozapine on hematological indices: A 1-Year Follow-Up Study. J Clin Psychopharmacol. 35:510–516. 2015.PubMed/NCBI View Article : Google Scholar
18	Matthews JN, Altman DG, Campbell MJ and Royston P: Analysis of serial measurements in medical research. BMJ. 300:230–235. 1990.PubMed/NCBI View Article : Google Scholar
19	Matthews JNS: A refinement to the analysis of serial data using summary measures. Stat Med. 12:27–37. 1993.PubMed/NCBI View Article : Google Scholar
20	Pichler WJ, Beeler A, Keller M, Lerch M, Posadas S, Schmid D, Spanou Z, Zawodniak A and Gerber B: Pharmacological interaction of drugs with immune receptors: The p-i concept. Allergol Int. 55:17–25. 2006.PubMed/NCBI View Article : Google Scholar
21	Boehme SA, Lio FM, Sikora L, Pandit TS, Lavrador K, Rao SP and Sriramarao P: Cutting edge: Serotonin is a chemotactic factor for eosinophils and functions additively with eotaxin. J Immunol. 173:3599–3603. 2004.PubMed/NCBI View Article : Google Scholar
22	Baganz NL and Blakely RD: A Dialogue between the immune system and brain, spoken in the language of serotonin. ACS Chem Neurosci. 4:48–63. 2013.PubMed/NCBI View Article : Google Scholar